Residency · Los Angeles, CA
Sponsored by Kaiser Permanente Southern California
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
The Lancet. Oncology · 2021 · 402 citations · Mehrdad Alemozaffar
CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor.
Immunity · 2023 · 307 citations · Mehrdad Alemozaffar
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
The Journal of urology · 2024 · 81 citations · Mehrdad Alemozaffar
Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 90 citations · Mehrdad Alemozaffar
NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025.
Journal of the National Comprehensive Cancer Network : JNCCN · 2025 · 30 citations · Ali Zhumkhawala
Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer.
JAMA · 2024 · 63 citations ·
An Analysis of American Urological Association Census Trends: Earlier Planned Retirement and Practice Pattern Changes May Exacerbate the Urology Workforce Shortage.
Urology · 2024 · 14 citations · Christopher Pellegrino, Gary Chien
Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage.
Histopathology · 2024 · 26 citations · Christopher Filson